PanTera is a Belgium-based joint venture formed by SCK CEN (the Belgian Nuclear Research Centre) and IBA (Ion Beam Applications). The company focuses on the production and supply of actinium‑225 (Ac‑225), a medical radioisotope used in targeted alpha radiopharmaceutical therapies, particularly in oncology.
PanTera’s activities cover isotope production, purification, quality control, and compliant distribution to pharmaceutical developers, hospitals, and research institutions. Leveraging SCK CEN’s nuclear science expertise and IBA’s accelerator and industrialization capabilities, the company is developing large-scale, GMP‑compliant Ac‑225 production capacity to improve the reliability of European and global supply. Its work supports preclinical research, clinical trials, and eventual commercial use of targeted radiopharmaceuticals.